AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2900252 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1.0 mg i.v.)
Number of subjects: 0
Study 2900252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol with islet clamp technique
Number of subjects: 0
Study 30851397 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Number of subjects: 124
Study 30851397 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 124
Study 31197369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) treatment sessions for quadriceps muscles over 16 weeks (36 sessions)
Number of subjects: 24
Study 31197369 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES training intensity
Number of subjects: 24
Study 31197369 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum NMES training intensity
Number of subjects: 24
Study 28277689 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship skills education
Number of subjects: 2540
Study 28277689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relationship skills education)
Number of subjects: 2540
Study 25461495 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced protein weight reduction (Protein) arm
Number of subjects: 0
Study 25461495 — intervention group
Group type: COMPARATOR
Intervention: Traditional weight loss (Control) arm
Number of subjects: 0
Study 23218533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Zolpidem 10mg
Number of subjects: 58
Study 23218533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Zolpidem 5mg
Number of subjects: 58
Study 23218533 — intervention group
Group type: COMPARATOR
Intervention: Oral Zolpidem 10mg
Number of subjects: 58
Study 16574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) 35 mug/h patch
Number of subjects: 46
Study 16574034 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl (DDTDF) 25 mug/h patch
Number of subjects: 46
Study 12811569 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow relaxation
Number of subjects: 22
Study 12811569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast relaxation
Number of subjects: 22
Study 9895016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride
Number of subjects: 10
Study 9895016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8724889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 585
Study 8724889 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 585
Study 8724889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 585
Study 8724889 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure goal
Number of subjects: 585
Study 1793781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg t.d.s., by rectal administration
Number of subjects: 69
Study 1793781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 6404471 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared coagulation (n=66)
Number of subjects: 137
Study 6404471 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (n=71)
Number of subjects: 137
Study 31101487 — intervention group
Group type: EXPERIMENTAL
Intervention: Edetate disodium-based chelation
Number of subjects: 162
Study 31101487 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 162
Study 27654854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg)
Number of subjects: 257
Study 27654854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 26466871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon (20 mg)
Number of subjects: 84
Study 26466871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 23642492 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 44
Study 23642492 — intervention group
Group type: COMPARATOR
Intervention: Sulthiame (STM)
Number of subjects: 44
Study 21729932 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 175
Study 21729932 — intervention group
Group type: COMPARATOR
Intervention: Standard Policy (SP)
Number of subjects: 175
Study 20491142 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperHAES solution (7.2% sodium chloride and hydroxyethyl starch 200/0.5)
Number of subjects: 25
Study 20491142 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% mannitol solution
Number of subjects: 25
Study 20491142 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium chloride solution
Number of subjects: 25
Study 17340596 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries preventive agent
Number of subjects: 0
Study 17340596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel logistic regression modelling
Number of subjects: 0
Study 15633327 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Number of subjects: 41
Study 15633327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11719739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g) plus intravenous metoclopramide (20 mg)
Number of subjects: 44
Study 11719739 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (20 mg) plus placebo (intravenous saline solution)
Number of subjects: 44
Study 11719739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate plus metoclopramide
Number of subjects: 44
Study 9167373 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 0.2 mg sublingually two hours before dilatation
Number of subjects: 31
Study 9167373 — intervention group
Group type: COMPARATOR
Intervention: pentazocine 30 mg intravenously five minutes before dilatation
Number of subjects: 31
Study 7701413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative therapy (FKT)
Number of subjects: 121
Study 7701413 — intervention group
Group type: EXPERIMENTAL
Intervention: FKT and Ditropan (1 tablet 3 times daily for weeks therapy)
Number of subjects: 121
Study 7701413 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy with electric functional stimulation (SEF)
Number of subjects: 121
Study 3295180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol depot (21 mg, single dose, p.o.)
Number of subjects: 131
Study 3295180 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (22.5 mg, three doses, p.o.)
Number of subjects: 131
Study 3295180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol depot
Number of subjects: 131
Study 3295180 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 131
Study 3295180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 131
Study 31727402 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position using a fracture table
Number of subjects: 0
Study 31727402 — intervention group
Group type: COMPARATOR
Intervention: Supine/sloppy lateral positioning
Number of subjects: 0
Study 31727402 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral positioning with leg free draped
Number of subjects: 0
Study 31727402 — intervention group
Group type: COMPARATOR
Intervention: Lateral positioning
Number of subjects: 0
Study 31727402 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in randomized control trial comparing lateral positioning vs. supine with traction
Number of subjects: 0
Study 29316341 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention during phase I
Number of subjects: 636
Study 29316341 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received intervention during phase II)
Number of subjects: 636
Study 29316341 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I intervention sites
Number of subjects: 636
Study 29262472 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 40
Study 26118944 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week duration of anticoagulation
Number of subjects: 100
Study 26118944 — intervention group
Group type: COMPARATOR
Intervention: 3-month duration of anticoagulation
Number of subjects: 100
Study 23597217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite (NaOCl)
Number of subjects: 24
Study 23597217 — intervention group
Group type: COMPARATOR
Intervention: 20% Formocresol (FC)
Number of subjects: 24
Study 21185153 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 21
Study 19630704 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking (intoxication)
Number of subjects: 0
Study 16563590 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 9
Study 16563590 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 9
Study 16563590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15344464 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-driven automated extraction method
Number of subjects: 30
Study 10858971 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 300
Study 10858971 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 300
Study 9382121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg alendronate
Number of subjects: 100
Study 9382121 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 100
Study 9382121 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg alendronate
Number of subjects: 100
Study 9382121 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg alendronate
Number of subjects: 100
Study 9382121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1313762 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day rice bran
Number of subjects: 18
Study 1313762 — intervention group
Group type: COMPARATOR
Intervention: 15 g/day wheat bran
Number of subjects: 18
Study 1313762 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day rice bran
Number of subjects: 18
Study 1313762 — intervention group
Group type: COMPARATOR
Intervention: 15 g wheat bran
Number of subjects: 18
Study 1313762 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g rice bran
Number of subjects: 18
Study 3933199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nightly for 3 years
Number of subjects: 1726
Study 3933199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1726
Study 3933199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nightly
Number of subjects: 1726
Study 31348430 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour exposure to brazing fumes
Number of subjects: 15
Study 31348430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour exposure to brazing fumes
Number of subjects: 15
Study 31348430 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour exposure to brazing fumes
Number of subjects: 15
Study 30020088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg orally 1 hour before surgery and at postoperative 12th and 24th hours
Number of subjects: 94
Study 30020088 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg orally 1 hour before surgery, placebo at postoperative 12th hour, and duloxetine 60 mg at 24th hour
Number of subjects: 94
Study 30020088 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules orally at all timepoints
Number of subjects: 94
Study 26706908 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing e-cigarette advertisements
Number of subjects: 5020
Study 26706908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5020
Study 24581401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest
Number of subjects: 110
Study 24581401 — intervention group
Group type: COMPARATOR
Intervention: Control (no weighted vest)
Number of subjects: 110
Study 22155172 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402
Study 22155172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 22155172 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402
Study 22155172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402
Study 19648021 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteum-polymer complex
Number of subjects: 3
Study 19648021 — intervention group
Group type: COMPARATOR
Intervention: Ilium
Number of subjects: 3
Study 16942923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training using the compact Erlangen Active Simulator for Interventional Endoscopy-simulator
Number of subjects: 27
Study 16942923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study 16288372 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV
Number of subjects: 0
Study 16288372 — intervention group
Group type: COMPARATOR
Intervention: Prior vaccination with OPV
Number of subjects: 0
Study 16288372 — intervention group
Group type: COMPARATOR
Intervention: Two doses of IPV
Number of subjects: 0
Study 12162817 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAVCF (100,000 replication units)
Number of subjects: 23
Study 12162817 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 10609245 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 5% phenylephrine and 1% cyclopentolate with digital compression by patients
Number of subjects: 75
Study 10609245 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 5% phenylephrine and 1% cyclopentolate with digital compression by investigators
Number of subjects: 75
Study 10609245 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative injection of epinephrine 1:25,000 in the anterior chamber
Number of subjects: 75
Study 7718375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 10
Study 7718375 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose isoflurane
Number of subjects: 10
Study 7718375 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SNP and isoflurane
Number of subjects: 10
Study 2248029 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid 300 mg, twice a day for seven consecutive days
Number of subjects: 40
Study 2248029 — intervention group
Group type: COMPARATOR
Intervention: placebo, twice a day for seven consecutive days
Number of subjects: 40
Study 7221983 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (7 mg)
Number of subjects: 21
Study 7221983 — intervention group
Group type: COMPARATOR
Intervention: Mustine (20 mg)
Number of subjects: 21
Study 29688123 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endovenous ablation of superficial venous reflux with compression therapy
Number of subjects: 450
Study 29688123 — intervention group
Group type: COMPARATOR
Intervention: Deferred endovenous ablation of superficial venous reflux with compression therapy
Number of subjects: 450
Study 28351379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg) for 3 days
Number of subjects: 120
Study 28351379 — intervention group
Group type: COMPARATOR
Intervention: Partial endodontic treatment
Number of subjects: 120
Study 25581605 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine incontinence care plus the suspension positioning system (SPS)
Number of subjects: 200
Study 25581605 — intervention group
Group type: COMPARATOR
Intervention: Routine FI nursing care (control group)
Number of subjects: 200
Study 23988341 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with CFE
Number of subjects: 100
Study 23988341 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 100
Study 23988341 — intervention group
Group type: EXPERIMENTAL
Intervention: CFE
Number of subjects: 100
Study 23988341 — intervention group
Group type: EXPERIMENTAL
Intervention: All ablation strategies
Number of subjects: 100
Study 21110172 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) high dose (six capsules, thrice a day)
Number of subjects: 126
Study 21110172 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) low dose (four capsules, thrice a day)
Number of subjects: 126
Study 21110172 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablets (four tablets, thrice a day)
Number of subjects: 126
Study 21110172 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) high dose
Number of subjects: 126
Study 21110172 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) low dose
Number of subjects: 126
Study 21110172 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablets
Number of subjects: 126
Study 18203047 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program (PEP)
Number of subjects: 33
Study 18203047 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group 2)
Number of subjects: 33
Study 18203047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population (both groups)
Number of subjects: 33
Study 18203047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 16299017 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term normobaric hypoxia (simulating 3636 m altitude, inspired O2=13%)
Number of subjects: 12
Study 16299017 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 12
Study 11965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoconjugates emitting beta-particles (e.g., 131I-anti-CD33, 90Y-anti-CD33, 131I-anti-CD45, 188Re-anti-CD66c)
Number of subjects: 0
Study 11965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoconjugates emitting alpha-particles (e.g., 213Bi-anti-CD33)
Number of subjects: 0
Study 11965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled antibodies
Number of subjects: 0
Study 11965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled antibodies used in conjunction with conditioning regimens
Number of subjects: 0
Study 9829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock exposure
Number of subjects: 0
Study 9829785 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 9829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative shock conditioning
Number of subjects: 0
Study 9829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant pictures
Number of subjects: 0
Study 7926293 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐absorbable ICAs
Number of subjects: 0
Study 7926293 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐nonabsorbable ICAs
Number of subjects: 0
Study 7926293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low positive levels of GAAs
Number of subjects: 0
Study 7926293 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of GAAs (1,800 cpm)
Number of subjects: 0
Study 7926293 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD autoantibodies (GAAs)
Number of subjects: 0
Study 2679680 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin (1 g:2 g) administered intravenously every 8 h
Number of subjects: 95
Study 2679680 — intervention group
Group type: COMPARATOR
Intervention: cefotetan (2 g) administered intravenously every 12 h
Number of subjects: 95
Study 19548446 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXT)
Number of subjects: 260
Study 19548446 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil
Number of subjects: 260
Study 428840 — intervention group
Group type: EXPERIMENTAL
Intervention: Actihaemyl (6 weeks, twice weekly 10 ml i.v.)
Number of subjects: 32
Study 30741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic latex pillow
Number of subjects: 42
Study 30741761 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy alone (Control)
Number of subjects: 42
Study 30741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic latex pillow with physical therapy
Number of subjects: 42
Study 29514682 — intervention group
Group type: EXPERIMENTAL
Intervention: Support workers delivering interventions to older people
Number of subjects: 100
Study 29514682 — intervention group
Group type: COMPARATOR
Intervention: Usual general practice care
Number of subjects: 100
Study 27762190 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+Pred
Number of subjects: 134
Study 27762190 — intervention group
Group type: COMPARATOR
Intervention: MTX+Plac
Number of subjects: 134
Study 25726209 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (hygienic‐dietary recommendations on diet, exercise, sleep, and sun exposure)
Number of subjects: 77
Study 25726209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 25726209 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (hygienic‐dietary recommendations)
Number of subjects: 77
Study 22825573 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopwatch urine stream interruption test (UST)
Number of subjects: 47
Study 19387233 — intervention group
Group type: EXPERIMENTAL
Intervention: Paragon CRT reverse geometry rigid gas permeable contact lenses (-2.00 diopters)
Number of subjects: 14
Study 19387233 — intervention group
Group type: EXPERIMENTAL
Intervention: Paragon CRT reverse geometry rigid gas permeable contact lenses (-4.00 diopters)
Number of subjects: 14
Study 17896170 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31
Study 17896170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 31
Study 15149710 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report depressive symptoms
Number of subjects: 2
Study 15149710 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-report anxiety symptoms
Number of subjects: 2
Study 12197896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 7